FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease

Illustration of enlarged view of regular cell and a sickle cell
Investigator(s): The Lundquist Institute

TORRANCE, Calif., May 24, 2017 /PRNewswire/ -- Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.

Read more

LA BioMed Sells Royalty Rights to Kybella® - Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities

Older white building with blue trim labeled C1 and C2
Investigator(s): The Lundquist Institute

LOS ANGELES – (May  18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.

Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.

Read more